FDA Approves Adzynma (ADAMTS13, recombinant-krhn) Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan& CAMBRIDGE, Mass., November 09, 2023--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved Adzynma (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news